Akari Therapeutics plc ADS (AKTX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Akari Therapeutics plc ADS (NASDAQ: AKTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $7.84 (-4.85% 1D, market cap $18.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AKTX ranks #547 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and COCP (Cocrystal Pharma Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $19.2M). Among the 5-stock peer group, AKTX leads on earnings multiple (N/A) while AKTX leads on capital efficiency (-35.0% ROIC).
Per AKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001541157), Akari Therapeutics plc ADS generated $48.4M in revenue (-20.2% YoY), -$17.3M in net income, and -$10.6M in free cash flow against $47.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 47.3 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While AKTX currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.30) and Max Pain ($8.23) forces dealer call-delta covering toward $35.28.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Akari Therapeutics plc ADS (AKTX) dropped -4.85% to $7.84, trading at 16% of its 52-week range ($3.02 – $33.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation Satyajit Mitra, Executive Director, Head of Oncology, to discuss d
Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved upwards by
XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.
CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities supporting AKTX-101’s advancement toward planned Phase 1 clinical development in mid-2027 Recent deal activity and emerging cl
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap stands at
Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value Mr. Vat-Ho brings highly re
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -20.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AKTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AKTX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Akari Therapeutics plc ADS (AKTX) ranks #547 by composite RQD confidence (37/100, grade D-) and #833 by equity capitalization ($18.8M). Within this direct 5-issuer industry benchmark cohort, AKTX leads on earnings valuation at N/A trailing P/E, while AKTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MCRB currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with AKTX at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AKTX
ACTIVE
Akari Therapeutics plc ADS | D- | 37/100 | — | — | -35.0% | -4.85% | $18.8M | Benchmark Subject |
| KYNB Kyntra Bio Inc. | E | 32/100 | — | 91.4% | -35.0% | -2.41% | $18.5M | /kynb-vs-aktx → |
| COCP Cocrystal Pharma Inc. | D- | 36/100 | — | — | -35.0% | +6.53% | $19.2M | /cocp-vs-aktx → |
| ACTU Actuate Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | +2.06% | $18.4M | /actu-vs-aktx → |
| MCRB Seres Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | +3.39% | $17.8M | /mcrb-vs-aktx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Akari Therapeutics plc ADS (AKTX) reported GAAP revenue of $48.4M (-20.2% vs. FY2024 revenue of $60.6M , and +13048.4% cumulative change since FY2023) , GAAP net income of -$17.3M, operating cash flow of -$10.6M, and free cash flow of -$10.6M (+15.8% YoY). On the balance sheet, AKTX closed FY2025 with $47.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $48.4M | -$17.3M | -$10.6M | -$10.6M | $47.9M | — |
| FY2024 (FY) | 2024-12-31 | $60.6M | -$19.8M | -$12.6M | -$12.6M | $50.6M | — |
| FY2023 (FY) | 2023-12-31 | $367.9K | -$10.0M | -$16.4M | -$16.4M | — | — |
As of 2026-11-03, Akari Therapeutics plc ADS (NASDAQ: AKTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $7.84 (-4.85% 1D, market cap $18.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AKTX ranks #547 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and COCP (Cocrystal Pharma Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $19.2M). Among the 5-stock peer group, AKTX leads on earnings multiple (N/A) while AKTX leads on capital efficiency (-35.0% ROIC).
Per AKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001541157), Akari Therapeutics plc ADS generated $48.4M in revenue (-20.2% YoY), -$17.3M in net income, and -$10.6M in free cash flow against $47.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
AKTX last traded at $7.84 (-4.85% on volume of 11,865 shares), positioning the stock -15.70% below its 50-day simple moving average ($9.30) and -13.18% below its 200-day simple moving average ($9.03). Across its 52-week range of $3.02 to $33.60, AKTX sits at the 15.8% percentile with a 14-day RSI of 47.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.86 to $8.82).
Akari Therapeutics plc ADS (AKTX) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $7.84 (-4.85% 1D, market capitalization $18.8M).
Akari Therapeutics plc ADS (AKTX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is reported as $0.0B, while the market data shows $18.3M. The company reported — of revenue in FY 2025 and FY 2024, and $0.4M in FY 2023. — for product lines, customers, or revenue model specifics.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Akari Therapeutics plc ADS (AKTX) reported $48.4M in annual revenue (up from $60.6M in FY2024, -20.2% YoY) and -$17.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($367.9K revenue, -$10.0M net income) through FY2025, AKTX scaled operating cash flow to -$10.6M and free cash flow to -$10.6M, backed by $47.9M in total assets against $0 in total debt.
— for upstream suppliers, downstream customers, or sector correlation mappings beyond the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification.
Real-time company headlines, analyst actions, and sector developments for Akari Therapeutics plc ADS (AKTX) • Click "Debate This Headline" to argue it in the Roar Pit below
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation Satyajit Mitra, Executive Director, Head of Oncology, to discuss d
Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved upwards by
XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.
CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities supporting AKTX-101’s advancement toward planned Phase 1 clinical development in mid-2027 Recent deal activity and emerging cl
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap stands at
Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value Mr. Vat-Ho brings highly re
Here is why I am bullish on AKTX here at $8.24: The Altman Z-Score of 2.5 and Debt/Equity of 0.5 suggest the balance sheet is not yet distressed despite cash burn.. Compare AKTX's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $7.83 are getting bought.
@DeltaGamma_99 Agree on the RQD 37/100 quality, though with 1.0 beta I'm scaling in with half-size at $8.24 and keeping dry powder in case we test $7.66.
Sitting on the sidelines or leaning short AKTX above $8.24. The company posted operating losses in every reported period with ROIC of -35%, zero revenue in FY 2025 and FY 2024, and a Piotroski F-Score of 2/9.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $33.60.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: